Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Dec 26;20(1):768.
doi: 10.1186/s13063-019-3803-8.

Effects of aerobic interval training on glucose tolerance in children and adolescents with cystic fibrosis: a randomized trial protocol

Karolinne Souza Monteiro  1   2 , Matheus de Paiva Azevedo  3 , Lucas Menescal Jales  3 , Fernanda Elizabeth Pereira da Silva  3 , Ricardo Fernando Arrais  4 , Karla Morganna Pereira Pinto de Mendonça  3
Affiliations
Randomized Controlled Trial

Effects of aerobic interval training on glucose tolerance in children and adolescents with cystic fibrosis: a randomized trial protocol

Karolinne Souza Monteiro et al. Trials. .

Abstract

Background: Individuals with cystic fibrosis (CF) may develop CF-related diabetes (CFDR). This comorbidity is related to a poorer quality of life, microvascular complications, a decline in lung function, and an increase in exacerbations, as well as delayed growth and puberty. Evidence exists that physical exercise contributes to glycemic control in individuals with non-CF-related diabetes. This exercise is usually continuous with moderate intensity and long duration, which can cause muscle dyspnea and fatigue in CF individuals. Aerobic interval training (AIT) emerges as a safe and effective alternative for treating these individuals. The objective of this study is to evaluate the effects of AIT on glucose tolerance in children and adolescents with CF.

Methods: This study will be a two-arm, prospectively registered, randomized controlled trial with blind assessors and twenty 6- to 18-year-old individuals with cystic fibrosis (CF) from two different Brazilian states. People with CF will be randomly allocated to either the experimental or control group using block randomization, stratified by puberty stage,. Participants from both groups will receive an educational intervention and will be asked to continue their usual daily treatment for the full duration of the study. Those in the experimental group will perform AIT on a cycle ergometer at home three times a week, for 8 consecutive weeks. The sample characterization will include an assessment of puberty stage, socioeconomic status, dyspnea, and anthropometry. The primary outcome will be the change in glucose tolerance, while the secondary outcomes will include lung function, exercise tolerance, respiratory muscle strength, quality of life, and CF exacerbations. All outcomes will be assessed at baseline, week 9, and week 17.

Discussion: This is the first study to evaluate the effects of AIT on glucose tolerance in children and adolescents with CF. This study will serve as a basis for guiding clinical practice and decision-making in treating glucose intolerance and CF-related diabetes (CFRD) in children and adolescents with CF.

Trial registration: ClinicalTrials.gov Protocol Registration System: NCT03653949. Registered on August 31, 2018.

Keywords: Cystic fibrosis, Glucose tolerance, Aerobic exercise, Exercise, Respiratory function tests.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of the planned protocol
Fig. 2
Fig. 2
Study design schedule in accordance with the standard protocol items: Recommendations for Interventional Trials (SPIRIT) checklist
See this image and copyright information in PMC

References

    1. Pritchard LL. Respiratory conditions update: cystic fibrosis. FP Essent. 2016;448:35–43. - PubMed
    1. Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–2531. doi: 10.1016/S0140-6736(16)00576-6. - DOI - PubMed
    1. Marquette M, Haworth CS. Bone health and disease in cystic fibrosis. Paediatr Respir Rev. 2016;20(Suppl):2–5. doi: 10.1016/j.prrv.2016.06.003. - DOI - PubMed
    1. Kamal N, Surana P, Koh C. Liver disease in patients with cystic fibrosis. Curr Opin Gastroenterol. 2018;34(00):1–6. doi: 10.1097/MOG.0000000000000432. - DOI - PMC - PubMed
    1. Quittner Alexandra L, Abbott Janice, Georgiopoulos Anna M, Goldbeck Lutz, Smith Beth, Hempstead Sarah E, Marshall Bruce, Sabadosa Kathryn A, Elborn Stuart. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety. Thorax. 2015;71(1):26–34. doi: 10.1136/thoraxjnl-2015-207488. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data